Neurogene
NGNE | NASDAQ
$23.30
-$0.63 (-2.63%)
At close: Nov 16, 2026, 4:00 PM ET
$23.30
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-2.63%
(1D)No price chart data available for 1D timeframe.
Rating
25.2
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #926/1021 (Top 91%)
Key Statistics
Market Data
Market Cap $645.31M
1D Range
23.20 24.55
52W Range
16.37 42.84
Valuation (TTM)
PE -4.18
PB 1.82
EV/EBITDA -2.53
Valuation (NTM)
Forward PE N/A
Forward PEG -0.23
Price Target $70.00
Cash Flow
FCF Yield -15.0%
SBC Adj. FCF Yield -17.0%
SBC Impact -13.4%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y -150.0% |
0.0%
Dil EPS 3Y | 5Y -103.9% |
-28.6%
FCF 3Y | 5Y -7.9% |
-18.8%
Returns
ROA -31.5%
ROE -44.4%
ROIC -35.8%
Financial Health
Net Cash
$359.72M
Current Ratio 19.97
Interest Coverage -129,924.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently fe...
Sector Healthcare
Industry Biotechnology
Employees 131
IPO Date Mar 7, 2014
Website www.neurogene.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
3
Consensus
Buy
Price Target
$70.00
Upside
+200.43%
Buy (3)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove NGNE